β1-integrins signaling and mammary tumor progression in transgenic mouse models: Implications for human breast cancer

Breast Cancer Research

Volumn 13, Issue 6, 2011, Pages

  Lahlou, Hicham ^a   Muller, William J ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTEGRIN; BETA LACTOGLOBULIN; BETA1 INTEGRIN; CD31 ANTIGEN; CD98 ANTIGEN; CRK ASSOCIATED SUBSTRATE PROTEIN; CRK LIKE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; FLUOROURACIL; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE 1; KALININ; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; PAXILLIN; PROTEIN P130; PROTEIN P85; TENASCIN; TRASTUZUMAB; VITRONECTIN; VOLOCIXIMAB;

BREAST CANCER; BREAST TUMOR; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL DIFFERENTIATION; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HEMIDESMOSOME; IN VIVO STUDY; MAMMARY GLAND; MOUSE MAMMARY TUMOR ONCOVIRUS; MULTIPLE SCLEROSIS; MYOEPITHELIUM CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; TRANSGENIC ANIMAL; ANIMAL; CELL TRANSFORMATION; DISEASE MODEL; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; HUMAN; METABOLISM; METASTASIS; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD29; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; MAMMARY GLANDS, HUMAN; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION;

EID: 84855829745     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2905     Document Type: Review

References (106)

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010, 19:1893-1907. 10.1158/1055-9965.EPI-10-0437, 20647400.
2. Sadikovic B, Al-Romaih K, Squire JA, Zielenska M. Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics 2008, 9:394-408. 10.2174/138920208785699580, 2691666, 19506729.
3. Guarneri V, Conte P. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist 2009, 14:645-656. 10.1634/theoncologist.2009-0078, 19608638.
4. Allred DC, Medina D. The relevance of mouse models to understanding the development and progression of human breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:279-288. 10.1007/s10911-008-9093-5, 18704660.
5. Brooks SA, Lomax-Browne HJ, Carter TM, Kinch CE, Hall DM. Molecular interactions in cancer cell metastasis. Acta Histochem 2010, 112:3-25. 10.1016/j.acthis.2008.11.022, 19162308.
6. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004, 5:816-826. 10.1038/nrm1490, 15459662.
7. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687. 10.1016/S0092-8674(02)00971-6, 12297042.
8. Zaidel-Bar R, Itzkovitz S, Ma'ayan A, Iyengar R, Geiger B. Functional atlas of the integrin adhesome. Nat Cell Biol 2007, 9:858-867. 10.1038/ncb0807-858, 2735470, 17671451.
9. Legate KR, Wickstrom SA, Fassler R. Genetic and cell biological analysis of integrin outside-in signaling. Genes Dev 2009, 23:397-418. 10.1101/gad.1758709, 19240129.
10. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10:9-22. 10.1038/nrc2748, 20029421.
11. Anthis NJ, Campbell ID. The tail of integrin activation. Trends Biochem Sci 2011, 36:191-198. 10.1016/j.tibs.2010.11.002, 21216149.
12. Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol 2007, 25:619-647. 10.1146/annurev.immunol.25.022106.141618, 1952532, 17201681.
13. Arnaout MA, Goodman SL, Xiong JP. Structure and mechanics of integrinbased cell adhesion. Curr Opin Cell Biol 2007, 19:495-507. 10.1016/j.ceb.2007.08.002, 2443699, 17928215.
14. Huveneers S, Danen EH. Adhesion signaling - crosstalk between integrins, Src and Rho. J Cell Sci 2009, 122(Pt 8):1059-1069.
15. Soung YH, Clifford JL, Chung J. Crosstalk between integrin and receptor tyrosine kinase signaling in breas t carcinoma progression. BMB Rep 2010, 43:311-318. 10.5483/BMBRep.2010.43.5.311, 20510013.
16. Caswell PT, Vadrevu S, Norman JC. Integrins: masters and slaves of endocytic transport. Nat Rev Mol Cell Biol 2009, 10:843-853. 10.1038/nrm2799, 19904298.
17. Brakebusch C, Fassler R. Beta1 integrin function in vivo: adhesion, migration and more. Cancer Metastasis Rev 2005, 24:403-411. 10.1007/s10555-005-5132-5, 16258728.
18. Taddei I, Faraldo MM, Teuliere J, Deugnier MA, Thiery JP, Glukhova MA. Integrins in mammary gland development and differentiation of mammary epithelium. J Mammary Gland Biol Neoplasia 2003, 8:383-394.
19. Aszodi A, Hunziker EB, Brakebusch C, Fassler R. Beta1 integrins regulate chondrocyte rotation, G1 progress ion, and cytokinesis. Genes Dev 2003, 17:2465-2479. 10.1101/gad.277003, 218082, 14522949.
20. Burkin DJ, Wallace GQ, Nicol KJ, Kaufman DJ, Kaufman SJ. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice. J Cell Biol 2001, 152:1207-1218. 10.1083/jcb.152.6.1207, 2199213, 11257121.
21. Schwander M, Leu M, Stumm M, Dorchies OM, Ruegg UT, Schittny J, Muller U. β1 integrins regulate myoblast fusion and sarcomere assembly. Dev Cell 2003, 4:673-685. 10.1016/S1534-5807(03)00118-7, 12737803.
22. Brakebusch C, Grose R, Quondamatteo F, Ramirez A, Jorcano JL, Pirro A, Svensson M, Herken R, Sasaki T, Timpl R, Werner S, Fassler R. Skin and hair follicle integrity is crucially dependent on beta 1 integrin expression on keratinocytes. EMBO J 2000, 19:3990-4003. 10.1093/emboj/19.15.3990, 306586, 10921880.
23. Belvindrah R, Graus-Porta D, Goebbels S, Nave KA, Muller U. Beta1 integrins in radial glia but not in migrating neurons are essential for the formation of cell layers in the cerebral cortex. J Neurosci 2007, 27:13854-13865. 10.1523/JNEUROSCI.4494-07.2007, 18077697.
24. Mettouchi A, Menegu zzi G. Distinct roles of β1 integrins during angiogenesis. Eur J Cell Biol 2006, 85:243-247. 10.1016/j.ejcb.2005.09.010, 16546568.
25. Anderson R, Fassler R, Georges-Labouesse E, Hynes RO, Bader BL, Kreidberg JA, Schaible K, Heasman J, Wylie C. Mouse primordial germ cells lacking β1 integrins enter the germline but fail to migrate normally to the gonads. Development 1999, 126:1655-1664.
26. Fassler R, Meyer M. Consequences of lack of beta 1 integrin gene expression in mice. Genes Dev 1995, 9:1896-1908. 10.1101/gad.9.15.1896, 7544313.
27. Stephens LE, Sutherla nd AE, Klimanskaya IV, Andrieux A, Meneses J, Pedersen RA, Damsky CH. Deletion of beta 1 integrins in mice results in inner cell mass failure and peri-implantation lethality. Genes Dev 1995, 9:1883-1895. 10.1101/gad.9.15.1883, 7544312.
28. Legate KR, Fassler R. Mechanisms that regulate adaptor binding to betaintegrin cytoplasmic tails. J Cell Sci 2009, 122(Pt 2):187-198.
29. Liu S, Calderwood DA, Ginsberg MH. Integrin cytoplasmic domain-binding proteins. J Cell Sci 2000, 113(Pt 20):3563-3571.
30. Regent M, Planus E, B ouin AP, Bouvard D, Brunner M, Faurobert E, Millon-Fremillon A, Block MR, Albiges-Rizo C. Specificities of beta(1) integrin signaling in the control of cell adhesion and adhesive strength. Eur J Cell Biol 2011, 90:261-269. 10.1016/j.ejcb.2010.09.006, 20971526.
31. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005, 6:56-68. 10.1038/nrm1549, 15688067.
32. Wennerberg K, Armulik A, Sakai T, Karlsson M, Fassler R, Schaefer EM, Mosher DF, Johansson S. The cytoplasmic tyrosines of integrin subunit β1 are involved in focal adhesion kinase activation. Mol Cell Biol 2000, 20:5758-5765. 10.1128/MCB.20.15.5758-5765.2000, 86053, 10891511.
33. Schaller MD, Otey CA, Hildebrand JD, Parsons JT. Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains. J Cell Biol 1995, 130:1181-1187. 10.1083/jcb.130.5.1181, 2120552, 7657702.
34. Brown MC, Turner CE. Paxillin: adapting to change. Physiol Rev 2004, 84:1315-1339. 10.1152/physrev.00002.2004, 15383653.
35. Thomas JW, Cooley MA, Broome JM, Salgia R, Griffin JD, Lombardo CR, Schaller MD. The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin. J Biol Chem 1999, 274:36684-36692. 10.1074/jbc.274.51.36684, 10593973.
36. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006, 18:516-523. 10.1016/j.ceb.2006.08.011, 16919435.
37. Playford MP, Schaller MD. The interplay between Src and integrins in normal and tumor biology. Oncogene 2004, 23:7928-7946. 10.1038/sj.onc.1208080, 15489911.
38. Mitra SK, Mikolon D, Molina JE, Hsia DA, Hanson DA, Chi A, Lim ST, Bernard-Trifilo JA, Ilic D, Stupack DG, Cheresh DA, Schlaepfer DD. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene 2006, 25:5969-5984. 10.1038/sj.onc.1209588, 16682956.
39. Xia H, Nho RS, Kahm J, Kleidon J, Henke CA. Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signaling pathway. J Biol Chem 2004, 279:33024-33034. 10.1074/jbc.M313265200, 15166238.
40. Gustavsson A, Yuan M, Fallman M. Temporal dissection of β1-integrin signaling indicates a role for p130Cas-Crk in filopodia formation. J Biol Chem 2004, 279:22893-22901. 10.1074/jbc.M309693200, 15044442.
41. Almeida EA, Ilic D, Han Q, Hauck CR, Jin F, Kawakatsu H, Schlaepfer DD, Damsky CH. Matrix survival signaling: from fibronectin via focal adhesion kinase to c-Jun NH(2)-terminal kinase. J Cell Biol 2000, 149:741-754. 10.1083/jcb.149.3.741, 2174844, 10791986.
42. Klinowska TC, Soriano J V, Edwards GM, Oliver JM, Valentijn AJ, Montesano R, Streuli CH. Laminin and β1 integrins are crucial for normal mammary gland development in the mouse. Dev Biol 1999, 215:13-32. 10.1006/dbio.1999.9435, 10525347.
43. Li N, Zhang Y, Naylor MJ, Schatzmann F, Maurer F, Wintermantel T, Schuetz G, Mueller U, Streuli CH, Hynes NE. Beta1 integrins regulate mammary gland proliferation and maintain the integrity of mammary alveoli. EMBO J 2005, 24:1942-1953. 10.1038/sj.emboj.7600674, 1142608, 15889143.
44. Naylor MJ, Li N, Cheung J, Lowe ET, Lambert E, Marlow R, Wang P, Schatzmann F, Wintermantel T, Schuetz G, Clarke AR, Mueller U, Hynes NE, Streuli CH. Ablation of β1 integrin in mammary epithelium reveals a key role for integrin in glandular morphogenesis and differentiation. J Cell Biol 2005, 171:717-728. 10.1083/jcb.200503144, 2171573, 16301336.
45. Pontier SM, Muller WJ. Integrins in mammary-stem-cell biology and breastcancer progression - a role in cancer stem cells?. J Cell Sci 2009, 122(Pt 2):207-214. 2714417, 19118213.
46. Taddei I, Deugnier MA, Faraldo MM, Petit V, Bouvard D, Medina D, Fassler R, Thiery JP, Glukhova MA. Beta1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nat Cell Biol 2008, 10:716-722. 10.1038/ncb1734, 2659707, 18469806.
47. Shaw LM. Integrin function in breast carcinoma progression. J Mammary Gland Biol Neoplasia 1999, 4:367-376. 10.1023/A:1018766317055, 10705920.
48. Litjens SH, de Pereda JM, S onnenberg A. Current insights into the formation and breakdown of hemidesmosomes. Trends Cell Biol 2006, 16:376-383. 10.1016/j.tcb.2006.05.004, 16757171.
49. Woodward TL, Mienaltowski A S, Modi RR, Bennett JM, Haslam SZ. Fibronectin and the alpha(5)beta(1) integrin are under developmental and ovarian steroid regulation in the normal mouse mammary gland. Endocrinology 2001, 142:3214-3222. 10.1210/en.142.7.3214, 11416044.
50. Novaro V, Roskelley CD, Bissell MJ. Collagen-IV and laminin-1 regulate estrogen receptor alpha expression and function in mouse mammary epithelial cells. J Cell Sci 2003, 116(Pt 14):2975-2986. 2933217, 12808020.
51. Gardner H, Kreidberg J, Koteliansky V, Jaenisch R. Deletion of integrin alpha 1 by homologous recombination permits normal murine development but gives rise to a specific deficit in cell adhesion. Dev Biol 1996, 175:301-313. 10.1006/dbio.1996.0116, 8626034.
52. Klinowska TC, Alexander CM, Georges-Labouesse E, Vander Neut R, Kreidberg JA, Jones CJ, Sonnenberg A, Streuli CH. Epithelial development and differentiation in the mammary gland is not dependent on alpha 3 or alpha 6 integrin subunits. Dev Biol 2001, 233:449-467. 10.1006/dbio.2001.0204, 11336507.
53. Chen J, Diacovo TG, Grenach e DG, Santoro SA, Zutter MM. The alpha(2) integrin subunit-deficient mouse: a multifaceted phenotype including defects of branching morphogenesis and hemostasis. Am J Pathol 2002, 161:337-344. 10.1016/S0002-9440(10)64185-5, 1850700, 12107118.
54. Lahlou H, Sanguin-Gendreau V, Zuo D, Cardiff RD, McLean GW, Frame MC, Muller WJ. Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci USA 2007, 104:20302-20307. 10.1073/pnas.0710091104, 2154426, 18056629.
55. White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, Mueller U, Muller WJ. Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 2004, 6:159-170. 10.1016/j.ccr.2004.06.025, 15324699.
56. Jones JL, Critchley DR, Walker RA. Alteration of stromal protein and integrin expression in breast - a marker of premalignant change?. J Pathol 1992, 167:399-406. 10.1002/path.1711670409, 1383484.
57. Jonjic N, Lucin K, Krstulja M, Iternicka Z, Mustac E. Expression of beta-1 integrins on tumor cells of invasive ductal breast carcinoma. Pathol Res Pract 1993, 189:979-984. 10.1016/S0344-0338(11)80668-0, 7508107.
58. Koukoulis GK, Virtanen I, Korhonen M, Laitinen L, Quaranta V, Gould VE. Immunohistochemical localization of integrins in the normal, hyperplastic, and neoplastic breast. Correlations with their functions as receptors and cell adhesion molecules. Am J Pathol 1991, 139:787-799. 1886301, 1928301.
59. Pignatelli M, Cardillo MR, Hanby A, Stamp GW. Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors. Hum Pathol 1992, 23:1159-1166. 10.1016/0046-8177(92)90034-Z, 1383121.
60. Zutter MM, Krigman HR, Santoro SA. Altered integrin expression in adenocarcinoma of the breast. Analysis by in situ hybridization. Am J Pathol 1993, 142:1439-1448. 1886906, 8388172.
61. Berry MG, Gui GP, Wells CA, Carpenter R. Integrin expression and survival in human breast cancer. Eur J Surg Oncol 2004, 30:484-489. 10.1016/j.ejso.2004.01.016, 15135474.
62. Gonzalez MA, Pinder SE, Wencyk PM, Bell JA, Elston CW, Nicholson RI, Robertson JF, Blamey RW, Ellis IO. An immunohistochemical examination of the expression of E-cadherin, α- and β/γ-catenins, and α2- and β1-integrins in invasive breast cancer. J Pathol 1999, 187:523-529. 10.1002/(SICI)1096-9896(199904)187:5<523::AID-PATH296>3.0.CO;2-3, 10398116.
63. Berry MG, Goode AW, Puddefoot J R, Vinson GP, Carpenter R. Integrin β1-mediated invasion of human breast cancer cells: an ex vivo assay for invasiveness. Breast Cancer 2003, 10:214-219. 10.1007/BF02966720, 12955033.
64. Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ, Bissell MJ. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 2006, 66:1526-1535. 10.1158/0008-5472.CAN-05-3071, 2933188, 16452209.
65. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997, 137:231-245. 10.1083/jcb.137.1.231, 2139858, 9105051.
66. Yao ES, Zhang H, Chen YY, Lee B, Chew K, Moore D, Park C. Increased β1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 2007, 67:659-664. 10.1158/0008-5472.CAN-06-2768, 17234776.
67. Lesniak D, Xu Y, Deschenes J, Lai R, Thoms J, Murray D, Gosh S, Mackey JR, Sabri S, Abdulkarim B. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res 2009, 69:8620-8628. 10.1158/0008-5472.CAN-09-1591, 19887601.
68. Golubovskaya VM, Kweh FA, Cance W G. Focal adhesion kinase and cancer. Histol Histopathol 2009, 24:503-510.
69. Watermann DO, Gabriel B, Jager M, Orlowska-Volk M, Hasenburg A, zur Hausen A, Gitsch G, Stickeler E. Specific induction of pp125 focal adhesion kinase in human breast cancer. Br J Cancer 2005, 93:694-698. 10.1038/sj.bjc.6602744, 2361616, 16136050.
70. Short SM, Yoder BJ, Tarr SM, Prescott NL, Laniauskas S, Coleman KA, Downs-Kelly E, Pettay JD, Choueiri TK, Crowe JP, Tubbs RR, Budd TG, Hicks DG. The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study. Breast J 2007, 13:130-139. 10.1111/j.1524-4741.2007.00389.x, 17319853.
71. Dorssers LC, Grebenchtchikov N, Brinkman A, Look MP, van Broekhoven SP, de Jong D, Peters HA, Portengen H, Meijer-van Gelder ME, Klijn JG, van Tienoven DT, Geurts-Moespot A, Span PN, Foekens JA, Sweep FC. The prognostic value of BCAR1 in patients with primary breast cancer. Clin Cancer Res 2004, 10(18 Pt 1):6194-6202.
72. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003, 163:2113-2126. 10.1016/S0002-9440(10)63568-7, 1892434, 14578209.
73. Marcotte R, Muller WJ. Signal transduction in transgenic mouse models of human breast cancer - implications for human breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:323-335. 10.1007/s10911-008-9087-3, 18651209.
74. Pontier SM, Muller WJ. Integrins in breast cancer dormancy. APMIS 2008, 116:677-684. 10.1111/j.1600-0463.2008.01026.x, 18834411.
75. Luo M, Fan H, Nagy T, Wei H, Wang C, Liu S, Wicha MS, Guan JL. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res 2009, 69:466-474. 10.1158/0008-5472.CAN-08-3078, 3039129, 19147559.
76. Provenzano PP, Inman DR, Eliceiri KW, Beggs HE, Keely PJ. Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer. Am J Pathol 2008, 173:1551-1565. 10.2353/ajpath.2008.080308, 2570144, 18845837.
77. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG. Rasand PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest 2009, 119:252-266. 2631302, 19147981.
78. Eccles SA. The role of c-erbB-2/H ER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 2001, 6:393-406. 10.1023/A:1014730829872, 12013529.
79. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007, 7:389-397. 10.1038/nrc2127, 17446858.
80. Huck L, Pontier SM, Zuo DM, Muller WJ. Beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc Natl Acad Sci USA 2010, 107:15559-15564. 10.1073/pnas.1003034107, 2932605, 20713705.
81. Ursini-Siegel J, Hardy WR, Zuo D, Lam SH, Sanguin-Gendreau V, Cardiff RD, Pawson T, Muller WJ. ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO J 2008, 27:910-920. 10.1038/emboj.2008.22, 2274931, 18273058.
82. Moro L, Dolce L, Cabodi S, Bergatto E, Boeri Erba E, Smeriglio M, Turco E, Retta SF, Giuffrida MG, Venturino M, Godovac-Zimmermann J, Conti A, Schaefer E, Beguinot L, Tacchetti C, Gaggini P, Silengo L, Tarone G, Defilippi P. Integrininduced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines. J Biol Chem 2002, 277:9405-9414. 10.1074/jbc.M109101200, 11756413.
83. Caswell PT, Chan M, Lindsay AJ, McCaffrey MW, Boettiger D, Norman JC. Rab-coupling protein coordinates recycling of α5β1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell Biol 2008, 183:143-155. 10.1083/jcb.200804140, 2557049, 18838556.
84. Liu Y, Pixley R, Fusaro M, Godoy G, Kim E, Bromberg ME, Colman RW. Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway. Oncogene 2009, 28:2756-2765. 10.1038/onc.2009.132, 2861141, 19483730.
85. Tagliabue E, Ghirelli C, Squicciarini P, Aiello P, Colnaghi MI, Menard S. Prognostic value of alpha 6 beta 4 integrin expression in breast carcinomas is affected by laminin production from tumor cells. Clin Cancer Res 1998, 4:407-410.
86. Chung J, Mercurio AM. Contributions of the alpha6 integrins to breast carcinoma survival and progression. Mol Cells 2004, 17:203-209.
87. Gilcrease MZ, Zhou X, Lu X, Woodwar d WA, Hall BE, Morrissey PJ. Alpha6beta4 integrin crosslinking induces EGFR clustering and promotes EGF-mediated Rho activation in breast cancer. J Exp Clin Cancer Res 2009, 28:67-76. 10.1186/1756-9966-28-67, 2694164, 19470173.
88. Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G, Giancotti FG. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 2006, 126:489-502. 10.1016/j.cell.2006.05.047, 16901783.
89. Pontier SM, Huck L, White DE, Rayment J, Sanguin-Gendreau V, Hennessy B, Zuo D, St-Arnaud R, Mills GB, Dedhar S, Marshall CJ, Muller WJ. Integrinlinked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer. Oncogene 2010, 29:3374-3385. 10.1038/onc.2010.86, 20305688.
90. Cabodi S, Tinnirello A, Di Stefano P, Bisaro B, Ambrosino E, Castellano I, Sapino A, Arisio R, Cavallo F, Forni G, Glukhova M, Silengo L, Altruda F, Turco E, Tarone G, Defilippi P. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res 2006, 66:4672-4680. 10.1158/0008-5472.CAN-05-2909, 16651418.
91. Taverna D, Crowley D, Connolly M, Bronson RT, Hynes RO. A direct test of potential roles for β3 and β5 integrins in growth and metastasis of murine mammary carcinomas. Cancer Res 2005, 65:10324-10329. 10.1158/0008-5472.CAN-04-4098, 16288021.
92. Ramirez NE, Zhang Z, Madamanchi A, Bo yd KL, O'Rear LD, Nashabi A, Li Z, Dupont WD, Zijlstra A, Zutter MM. The αβ integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest 2011, 121:226-237. 10.1172/JCI42328, 3007139, 21135504.
93. Yoshimura K, Meckel KF, Laird LS, Chia CY, Park JJ, Olino KL, Tsunedomi R, Harada T, Iizuka N, Hazama S, Kato Y, Keller JW, Thompson JM, Chang F, Romer LH, Jain A, Iacobuzio-Donahue C, Oka M, Pardoll DM, Schulick RD. Integrin α2 mediates selective metastasis to the liver. Cancer Res 2009, 69:7320-7328. 10.1158/0008-5472.CAN-09-0315, 19738067.
94. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010, 9:804-820. 10.1038/nrd3266, 20885411.
95. Bhaskar V, Zhang D, Fox M, Seto P, Wong M H, Wales PE, Powers D, Chao DT, Dubridge RB, Ramakrishnan V. A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Transl Med 2007, 5:61-71. 10.1186/1479-5876-5-61, 2235829, 18042290.
96. Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJ. A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 2011, 121:273-279. 10.1016/j.ygyno.2010.12.362, 21276608.
97. Bhaskar V, Fox M, Breinberg D, Wong MH, Wales PE, Rhodes S, DuBridge RB, Ramakrishnan V. Volociximab, a chimeric integrin α5β1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest New Drugs 2008, 26:7-12. 10.1007/s10637-007-9078-z, 17786386.
98. Donate F, Parry GC, Shaked Y, Hensley H, Guan X, Beck I, Tel-Tsur Z, Plunkett ML, Manuia M, Shaw DE, Kerbel RS, Mazar AP. Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a Ushaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clin Cancer Res 2008, 14:2137-2144. 10.1158/1078-0432.CCR-07-4530, 18381955.
99. Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, Donate F, Shaw DE, Mazar AP, Rabbani SA. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther 2006, 5:2271-2280. 10.1158/1535-7163.MCT-06-0100, 16985061.
100. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry GC, Parikh AA, McCarty MF, Bucana CD, Mazar AP, Ellis LM. Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 2003, 104:496-503. 10.1002/ijc.10958, 12584749.
101. Nam JM, Chung Y, Hsu HC, Park CC. Beta1 integrin targeting to enhance radiation therapy. Int J Radiat Biol 2009, 85:923-928. 10.3109/09553000903232876, 19895268.
102. Park CC, Zhang HJ, Yao ES, Park CJ, Bissell MJ. Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res 2008, 68:4398-4405. 10.1158/0008-5472.CAN-07-6390, 18519702.
103. Faschinger A, Rouault F, Sollner J, Lukas A, Salmons B, Gunzburg WH, Indik S. Mouse mammary tumor virus integration site selection in human and mouse genomes. J Virol 2008, 82:1360-1367. 10.1128/JVI.02098-07, 2224419, 18032509.
104. Andrechek ER, Hardy WR, Siegel PM, Rudnicki MA, Cardiff RD, Muller WJ. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci USA 2000, 97:3444-3449. 10.1073/pnas.050408497, 16259, 10716706.
105. Ricart AD, Tolcher AW, Liu G, Holen K, Schwartz G, Albertini M, Weiss G, Yazji S, Ng C, Wilding G. Volociximab, a chimeric monoclonal antibody that specifically binds α5β1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 2008, 14:7924-7929. 10.1158/1078-0432.CCR-08-0378, 19047123.
106. Cianfrocca ME, Kimmel KA, Gallo J, Cardoso T, Brown MM, Hudes G, Lewis N, Weiner L, Lam GN, Brown SC, Shaw DE, Mazar AP, Cohen RB. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer 2006, 94:1621-1626. 2361324, 16705310.